Anzeige
Mehr »
Mittwoch, 23.09.2026 - Börsentäglich über 12.000 News
Brandneue News liefert jetzt Teil 2 dieser Kupfer-Story
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
ACCESS Newswire
178 Leser
Artikel bewerten:
(1)

OMP and PwC Alliance Moves Process Manufacturers from Siloed Supply Chain Planning to Unified Decisions

Specialty pharmaceutical company medac has moved its planners onto a single demand plan. PwC and medac present the rollout and the road ahead at OMP's Singapore event on October 15, 2026.

ANTWERPEN, BE / ACCESS Newswire / September 23, 2026 / OMP and PwC have formed an alliance to bring unified, faster supply chain decisions to process manufacturers in life sciences, consumer goods, and chemicals. Planning in these industries runs on campaign production, long lead times, and regulatory requirements, all surfacing "too late to act on" when planning sits in separate systems. The alliance combines Unison Planning, OMP's AI-enabled planning platform with built-in industry expertise, and PwC's implementation services.

German specialty pharmaceutical company medac is already live under the alliance, with its planners working on a single demand plan in Unison Planning. PwC and medac will present the project on October 15, 2026, at the OMP Conference in Singapore, detailing the approach behind the rollout and what it means for planning in pharma.

Combining innovation, industry knowledge, and integration

OMP and PwC run each implementation as a single program. OMP brings Unison Planning, its AI-enabled platform with built-in industry expertise, connecting to the systems that a manufacturer already runs. PwC's teams lead the implementation, acting as system integrator and working directly alongside the customer's own planners.

Both organizations see the same shift across life sciences, consumer goods, and chemicals: manufacturers replacing fragmented planning with a unified end-to-end plan, and looking for a platform and an implementation team that already know their industry.

"Process manufacturers face the same planning constraints, whatever their size, and few have spare program capacity to absorb an implementation. That is where the combination of the platform, the industry knowledge, and an integrator who can run the program matters most," said Dieter Sleeuwaert, Senior Vice President Global Alliances at OMP.

medac moves from spreadsheets to a single demand plan

medac supplies specialty treatments in rheumatology, urology, hematology, and oncology to more than 90 countries, manufacturing at its own European sites. Its planning ran on a mix of spreadsheets, planning functions within its existing ERP system, and a separate tool with limited planning capability. Processes also differed by department and by geography.

PwC, medac and OMP started with a focused demand planning release, resulting in an accelerated go-live for German planners ahead of the wider rollout. The remaining geographies, a supply planning layer, and a second release running in parallel with medac's SAP S/4 implementation will follow.

"Leading with the demand planning release and holding the solution close to standard is what made it work. That approach transfers to other companies in the sector," said Jörg Zietz, Director, Supply Chain Planning at PwC Germany.

PwC and medac on stage in Singapore

Dr. Karsten Gentner, Vice President Supply Chain Management and Procurement at medac, and Jörg Zietz of PwC Germany will explain how medac is building the digital backbone for a smarter, more resilient, and AI-ready pharmaceutical supply chain. Their session takes place on October 15, 2026 at the OMP Conference in Singapore. Register for the event.

About PwC

At PwC, we help clients build trust and reinvent so they can turn complexity into a competitive advantage. We're a tech-forward, people-empowered network with more than 364,000 people in 136 countries and 137 territories. Across audit and assurance, tax and legal, deals and consulting, we help clients build, accelerate, and sustain momentum.

About medac

The medac Group is committed to improving patients' quality of life worldwide by providing access to the best possible medical therapies. As a globally operating pharmaceutical company headquartered in Germany, we are active in more than 90 countries and employ over 2,000 people worldwide. With production sites in Europe and a focus on rheumatology, urology, hematology, and oncology, medac develops and markets high-quality originator products, generics, and biosimilars.

About OMP

OMP helps companies facing complex planning challenges to excel, grow, and thrive by offering the best digitized supply chain planning solution on the market. Hundreds of customers in a wide range of industries - spanning consumer goods, life sciences, chemicals, metals, paper, packaging, plastics, tires, and building products - benefit from using OMP's unique Unison Planning.

Solution and product inquiries

Contact OMP
+32 3 650 22 11

Media inquiries
Kira Perdue (Carabiner)

SOURCE: OMP



View the original press release on ACCESS Newswire:
https://www.accessnewswire.com/newsroom/en/computers-technology-and-internet/omp-and-pwc-alliance-moves-process-manufacturers-from-siloed-supp-1224570

© 2026 ACCESS Newswire
KI-Euphorie kippt - Bei diesen 5 Aktien droht der Crash!
Drei Jahre lang kannten KI-Aktien fast nur eine Richtung: nach oben. Billionenschwere Investitionspläne von Alphabet, Amazon, Meta und Microsoft haben Halbleiter- und Infrastrukturwerte auf immer neue Höhen getrieben. Doch jetzt bekommt die Erfolgsstory gefährliche Risse.

Steigende Anleiherenditen verteuern die Finanzierung, während die gewaltigen KI-Ausgaben zunehmend nicht mehr aus den laufenden Cashflows bezahlt werden können. Gleichzeitig zeigen günstigere chinesische Modelle, dass leistungsfähige KI womöglich mit deutlich weniger Rechenleistung auskommt. Damit wächst die Gefahr, dass heute für Milliarden errichtete Kapazitäten morgen nicht die erhofften Renditen liefern.

Für Anleger könnte das zum Problem werden. Denn treffen steigende Finanzierungskosten auf Überkapazitäten und enttäuschende Cashflows, geraten gerade hoch bewertete KI-Profiteure schnell unter Druck. Aus den größten Gewinnern der vergangenen Jahre könnten so die größten Verlierer der nächsten Korrektur werden.

In unserem aktuellen Spezialreport zeigen wir 5 Aktien, bei denen das Chance-Risiko-Verhältnis jetzt besonders gefährlich erscheint – und bei denen Anleger genauer hinschauen sollten.

Jetzt den kostenlosen Report sichern – bevor die KI-Euphorie ihren nächsten Realitätstest erlebt!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.